Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Welcer

Physician Assistant, Surgical Grand Junction, CO Physician Assistant

NPI 1356689467 CMS profile 10799113

2373 G Rd, Suite 100, Grand Junction, CO 81501

Open in the dashboard

General payments

$2,869

106 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Welcer of Grand Junction, CO is reported in the CMS Open Payments database as having received $2,869 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91 1
2024 General $572 7
2023 General $651 31
2022 General $967 46
2021 General $587 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Welcer
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Amanda Welcer were reported at $91. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Amanda Welcer Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $587 $111 $36–$285 $132
2022 $967 $126 $44–$350 $149
2023 $651 $137 $47–$355 $160
2024 $572 $146 $49–$384 $164
2025 $91 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $407 30 payments
  2. Lilly USA, LLC $314 5 payments
  3. Neurocrine Biosciences, Inc. $249 3 payments
  4. Novartis Pharmaceuticals Corporation $235 7 payments
  5. Biogen, Inc. $232 5 payments
  6. Genentech USA, Inc. $163 2 payments
  7. Acorda Therapeutics, Inc $125 4 payments
  8. TG Therapeutics, Inc. $92 1 payment
  9. Medical Device Business Services, Inc. $91 1 payment
  10. Amneal Pharmaceuticals LLC $86 4 payments
  11. Other $875 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,869 106 payments
Products named General payments · program years 2021–2025
  1. TYSABRI $232 5 payments
  2. VUMERITY $232 5 payments
  3. OCREVUS $163 2 payments
  4. KESIMPTA $156 3 payments
  5. NURTEC ODT $137 8 payments
  6. INGREZZA Neuropsychiatry $134 2 payments
  7. INBRIJA $125 4 payments
  8. INGREZZA Neurology $115 1 payment
  9. QULIPTA $107 10 payments
  10. KISUNLA $105 1 payment
  11. Other $1,553 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,171

Median for Physician Assistant: 241

Drug cost

$1,314,301

Median for Physician Assistant: $4,110

Branded share of claims

44.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 45 $479,467
Ingrezza Valbenazine Tosylate Brand 25 $241,349
Rytary Carbidopa/Levodopa Brand 51 $119,626
Emgality Pen Galcanezumab-Gnlm Brand 77 $107,091
Nurtec Odt Rimegepant Sulfate Brand 42 $61,543
Qulipta Atogepant Brand 36 $54,999
Ubrelvy Ubrogepant Brand 43 $53,263
Neupro Rotigotine Brand 46 $49,322
Epidiolex Cannabidiol (Cbd) Brand 14 $31,926
Briviact Brivaracetam Brand 13 $26,563

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$85,807

Of which drugs: $37,199

Medicare patients

324

Average age 75

Services billed

8,648

168 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 49%
Depression 39%
Alzheimer's or dementia 23%
Osteoporosis 19%
Chronic kidney disease 18%
Ischemic heart disease 17%
Diabetes 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 14 7,300 $35,959

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $120
$120 — —
KISUNLA
  • Lilly USA, LLC $105
$105 — —
AMYVID
  • Lilly USA, LLC $94
$94 — —
BRIUMVI
  • TG Therapeutics, Inc. $92
$92 — —
DUOPA
  • AbbVie, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record